Neuroendocrine Tumor Clinical Trials in Bethesda, Maryland
13 recruitingBethesda, Maryland
Showing 1–13 of 13 trials
Recruiting
Phase 1
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
Neuroendocrine TumorsCarcinoma, NeuroendocrineNeuroendocrine Carcinomas+2 more
National Cancer Institute (NCI)70 enrolled1 locationNCT06041516
Recruiting
Phase 1
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Nasopharyngeal CarcinomaKidney CancersEsthesioneuroblastoma+7 more
National Cancer Institute (NCI)120 enrolled1 locationNCT06479811
Recruiting
Phase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Metastatic Breast CarcinomaMetastatic Ovarian CancerMetastatic Pancreatic Cancer+2 more
National Cancer Institute (NCI)332 enrolled1 locationNCT01174121
Recruiting
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Non-small Cell Lung CancerSmall Cell Lung CancerExtrapulmonary Small Cell Cancer+2 more
National Cancer Institute (NCI)2,000 enrolled1 locationNCT02146170
Recruiting
Phase 2
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Small Cell Carcinoma of the BladderHigh Grade Neuroendocrine Tumors of the Urinary Tract
National Cancer Institute (NCI)45 enrolled1 locationNCT06228066
Recruiting
Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Pancreatic Neuroendocrine TumorVon Hippel-Lindau DiseasePheochromocytoma/Paraganglioma+2 more
Merck Sharp & Dohme LLC355 enrolled84 locationsNCT04924075
Recruiting
Phase 2
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Breast CancerOvarian CancerNon-small Cell Lung Cancer+4 more
National Cancer Institute (NCI)285 enrolled1 locationNCT03412877
Recruiting
Phase 1Phase 2
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Neuroendocrine TumorsNeuroendocrine NeoplasmsGastroenteropancreatico Tumors
National Cancer Institute (NCI)56 enrolled1 locationNCT04086485
Recruiting
Phase 2
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Neuroendocrine TumorsParagangliomaPheochromocytoma+1 more
National Cancer Institute (NCI)130 enrolled1 locationNCT03206060
Recruiting
Phase 2
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Neuroendocrine TumorsVon Hippel-Lindau DiseaseVHL Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)740 enrolled1 locationNCT04074135
Recruiting
Phase 1Phase 2
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
PheochromocytomaGastrointestinal Neuroendocrine TumorsSomatostatin Receptor Positive+1 more
National Cancer Institute (NCI)66 enrolled1 locationNCT06427798
Recruiting
Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
Neuroendocrine TumorsCarcinoma, Neuroendocrine
National Cancer Institute (NCI)300 enrolled1 locationNCT05237934
Recruiting
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Breast CancerOvarian CancerEndometrial Cancer+40 more
Massive Bio, Inc.50,000 enrolled68 locationsNCT03452774